Australia markets closed

Cellectar Biosciences Inc (NV4.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
2.1000-0.1000 (-4.55%)
At close: 08:08PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
-
Operating expenses
Research development
28,935
28,211
19,220
17,586
10,141
-
Selling general and administrative
13,322
10,749
9,594
6,545
5,150
-
Total operating expenses
42,257
38,961
28,814
24,131
15,290
-
Operating income or loss
-42,257
-38,961
-28,814
-24,131
-15,290
-
Total other income/expenses net
-
530
-
6.634
185.28
43
Income before tax
-51,044
-38,043
-28,661
-24,122
-15,094
-
Income tax expense
-
-60
-60
0
-
-
Income from continuing operations
-50,984
-37,983
-28,601
-24,122
-15,094
-
Net income
-50,984
-37,983
-28,601
-24,122
-15,094
-
Net income available to common shareholders
-50,984
-37,983
-28,601
-24,122
-15,094
-
Basic EPS
-3.26
-3.11
-4.05
-4.35
-7.60
-
Diluted EPS
-3.26
-3.11
-4.05
-4.35
-7.60
-
Basic average shares
10,931
12,222
7,056
5,552
1,981
-
Diluted average shares
10,931
12,222
7,056
5,552
1,981
-